181 related articles for article (PubMed ID: 31419928)
1. Small Molecular Gemcitabine Prodrugs for Cancer Therapy.
Miao H; Chen X; Luan Y
Curr Med Chem; 2020; 27(33):5562-5582. PubMed ID: 31419928
[TBL] [Abstract][Full Text] [Related]
2. Recent Development of Prodrugs of Gemcitabine.
Pandit B; Royzen M
Genes (Basel); 2022 Mar; 13(3):. PubMed ID: 35328020
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties.
Hong S; Fang Z; Jung HY; Yoon JH; Hong SS; Maeng HJ
Molecules; 2018 Oct; 23(10):. PubMed ID: 30314360
[TBL] [Abstract][Full Text] [Related]
4. H-gemcitabine: a new gemcitabine prodrug for treating cancer.
Dasari M; Acharya AP; Kim D; Lee S; Lee S; Rhea J; Molinaro R; Murthy N
Bioconjug Chem; 2013 Jan; 24(1):4-8. PubMed ID: 23237198
[TBL] [Abstract][Full Text] [Related]
5. Acid-Triggered Release of Native Gemcitabine Conjugated in Polyketal Nanoparticles for Enhanced Anticancer Therapy.
Zhong H; Mu J; Du Y; Xu Z; Xu Y; Yu N; Zhang S; Guo S
Biomacromolecules; 2020 Feb; 21(2):803-814. PubMed ID: 31995366
[TBL] [Abstract][Full Text] [Related]
6. N-Acyl-phosphoramidates as potential novel form of gemcitabine prodrugs.
Baraniak J; Pietkiewicz A; Kaczmarek R; Radzikowska E; Kulik K; Krolewska K; Cieslak M; Krakowiak A; Nawrot B
Bioorg Med Chem; 2014 Apr; 22(7):2133-40. PubMed ID: 24631359
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of oral prodrugs based on the structure of gemcitabine.
Zhao C; Xue X; Li G; Sun C; Sun C; Qu X; Li W
Chem Biol Drug Des; 2012 Sep; 80(3):479-88. PubMed ID: 22642666
[TBL] [Abstract][Full Text] [Related]
8. Polygemcitabine nanogels with accelerated drug activation for cancer therapy.
Ma Y; Mou Q; Zhu L; Su Y; Jin X; Feng J; Yan D; Zhu X; Zhang C
Chem Commun (Camb); 2019 Jun; 55(46):6603-6606. PubMed ID: 31119252
[TBL] [Abstract][Full Text] [Related]
9. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport.
Song X; Lorenzi PL; Landowski CP; Vig BS; Hilfinger JM; Amidon GL
Mol Pharm; 2005; 2(2):157-67. PubMed ID: 15804190
[TBL] [Abstract][Full Text] [Related]
10. Multifunctional Tumor-Targeting Cathepsin B-Sensitive Gemcitabine Prodrug Covalently Targets Albumin in Situ and Improves Cancer Therapy.
Zhang H; Sun Z; Wang K; Li N; Chen H; Tan X; Li L; He Z; Sun J
Bioconjug Chem; 2018 Jun; 29(6):1852-1858. PubMed ID: 29775284
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy.
Bui DT; Nicolas J; Maksimenko A; Desmaële D; Couvreur P
Chem Commun (Camb); 2014 May; 50(40):5336-8. PubMed ID: 24185552
[TBL] [Abstract][Full Text] [Related]
12. Amphiphilic Dendritic Nanomicelle-Mediated Delivery of Gemcitabine for Enhancing the Specificity and Effectiveness.
Zhao W; Yang S; Li C; Li F; Pang H; Xu G; Wang Y; Cong M
Int J Nanomedicine; 2022; 17():3239-3249. PubMed ID: 35924258
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma.
Stephenson AA; Cao S; Taggart DJ; Vyavahare VP; Suo Z
Eur J Med Chem; 2021 Mar; 213():113135. PubMed ID: 33454548
[TBL] [Abstract][Full Text] [Related]
15. Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity.
Zhu S; Lansakara-P DS; Li X; Cui Z
Bioconjug Chem; 2012 May; 23(5):966-80. PubMed ID: 22471294
[TBL] [Abstract][Full Text] [Related]
16. Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.
Senanayake TH; Warren G; Wei X; Vinogradov SV
J Control Release; 2013 Apr; 167(2):200-9. PubMed ID: 23385032
[TBL] [Abstract][Full Text] [Related]
17. New anticancer agents in clinical development.
Eckardt J; Eckhardt G; Villalona-Calero M; Drengler R; Von Hoff D
Oncology (Williston Park); 1995 Dec; 9(12):1321-8; 1331; discussion 1332-4. PubMed ID: 8771106
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine.
Bender DM; Bao J; Dantzig AH; Diseroad WD; Law KL; Magnus NA; Peterson JA; Perkins EJ; Pu YJ; Reutzel-Edens SM; Remick DM; Starling JJ; Stephenson GA; Vaid RK; Zhang D; McCarthy JR
J Med Chem; 2009 Nov; 52(22):6958-61. PubMed ID: 19860433
[TBL] [Abstract][Full Text] [Related]
19. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
Immordino ML; Brusa P; Rocco F; Arpicco S; Ceruti M; Cattel L
J Control Release; 2004 Dec; 100(3):331-46. PubMed ID: 15567500
[TBL] [Abstract][Full Text] [Related]
20. Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.
Tsume Y; Drelich AJ; Smith DE; Amidon GL
Molecules; 2017 Aug; 22(8):. PubMed ID: 28796151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
